未登录

P

Patrick Marquis

University of Queensland

H指数:44

被引数:8,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma

ONCOLOGY AND THERAPY

IF3.2

2024-10-010

OAAI

Development and Preliminary Validation of an Instrument to Measure Symptoms and Impacts in Patients with Proliferative Diabetic Retinopathy

ADVANCES IN THERAPY

IF4

2023-02-270

OAAI

Development of a Conceptual Model of the Patient Experience in Small Cell Lung Cancer: A Qualitative Interview Study

ONCOLOGY AND THERAPY

IF3.2

2023-02-174

OAAI

I Can't Take off My Shirt or Do My Own Hair-A Qualitative Investigation of the Symptoms and Impact Experience of Children and Adolescents with Fibrodysplasia Ossificans Progressiva (FOP)

ADVANCES IN THERAPY

IF4

2022-04-160

OAAI

Measuring the Patient Experience in Rare Disorders: Benefit of Pragmatic Mixed-Methods Research in NUT Carcinoma

ONCOLOGY AND THERAPY

IF3.2

2022-03-175

OAAI

Understanding the Patient Experience in NUT Carcinoma: Qualitative Interviews with Patients and Caregivers to Develop a Conceptual Framework

ONCOLOGY AND THERAPY

IF3.2

2021-08-061

OAAI

Report First Documentation of Persistent SARS-Cov-2 Infection Presenting With Late Acute Severe Myocarditis

CANADIAN JOURNAL OF CARDIOLOGY

IF5.3

2020-08-0118

OAAI

Postictal stereo-EEG changes following bilateral tonic-clonic seizures

IF6.6

2019-07-027

OAAI

Impacts of Type 1 Diabetes on Patients during the First Two Years-A Qualitative Research Study

IF7.5

2018-07-011

PRE

Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH

IF3.1

2018-06-1959

OAAI

UNDERSTANDING PATIENTS' ABILITY TO FUNCTION IN ORDER TO INFORM CLINICAL BENEFIT IN ONCOLOGY STUDIES

VALUE IN HEALTH

IF6

2017-10-010

OAAI

Plasma levels of Macrophage Migration inhibitory Factor and D-Dopachrome Tautomerase show a highly specific Profile in early life

巨噬细胞移动抑制因子和D-多巴染色体互变异构酶的血浆水平在生命早期显示出高度特异性的特征

FRONTIERS IN IMMUNOLOGY

IF5.9

2017-01-2527

OAAI

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force

临床医生报告的治疗益处结果评估: ISPOR临床结果评估新兴良好实践工作组的报告

VALUE IN HEALTH

IF6

2017-01-01111

OAAI

MEASURING THE IMPACT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN THE ASCEND TRIAL: EQUATING THE MSIS-29, MSWS-12, ABILHAND-56 AND SF-36

VALUE IN HEALTH

IF6

2015-11-011

OAAI

Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force

临床结果评估: 概念基础-ISPOR临床结果评估报告-结果研究工作组的新兴良好实践

VALUE IN HEALTH

IF6

2015-09-01206

OAAI

MEASURING UPER LIMB FUNCTION IN MULTIPLE SCLEROSIS: ENHANCING THE ABILHAND'S PERFORMANCE

VALUE IN HEALTH

IF6

2015-05-012

OAAI

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY

IF3

2014-06-0114

OAAI

THE ROLE OF HEALTH-RELATED QUALITY OF LIFE DATA IN THE DRUG APPROVAL PROCESSES IN THE UNITED STATES AND EUROPE: A REVIEW OF GUIDANCE DOCUMENTS AND AUTHORIZATIONS OF MEDICINAL PRODUCTS FROM 2006 TO 2010

VALUE IN HEALTH

IF6

2011-05-010

OAAI

PRO development: rigorous qualitative research as the crucial foundation

QUALITY OF LIFE RESEARCH

IF2.7

2010-05-30430

OAAI

RECOMMENDATIONS FOR THE USE OF PATIENT REPORTED OUTCOMES TO ASSESS TREATMENT EFFICACY IN CLINICAL GUIDANCE DOCUMENTS RELEASED BY THE FDA AND EMEA

VALUE IN HEALTH

IF6

2009-10-011

OAAI